灵麦快讯LMLB119 【干货】逆天黑科技 :阿尔兹海默症“疫苗”最新临床进展

灵麦医药

欢迎分享,转载有版权, 请登录 lingmed.net/reports 下载全文


本周灵麦医药推荐一篇关于阿尔兹海默症疫苗最新临床进展的分析报告。  


阿尔兹海默症(AD),即我们平时所说的老年痴呆,是一种多发于中老年人群体的不可逆的中枢神经退行性病变。根据WHO数据显示,全球共有约4750万病人,每年约770万新增病例,且随着全球老年化趋势的加剧,未来阿尔兹海默症必将成为危害人类健康的一大难题。然而,近几十年来,在人类与该病的拉锯战中,人类的聪明才智好似一直都处于下风状态。回想去年11月,当礼来宣布其研发了27年,投资了30亿美金的药物Solanezumab的三期临床试验失败时,医药届的一片片扼腕叹息之声还历历在目。


难道医学界就该就此放弃?

接受没有任何可以治愈AD药物的事实么?

不可能!


最新AD疫苗的出现为AD的治疗带来了一丝曙光,不过哪个项目最安全?最具有市场潜力呢? 

摆脱过去,展望未来

三个特异性靶向β-淀粉样蛋白项目的最新临床进展

两个与Tau蛋白“纠缠”的项目的最新临床进展 


Therapy focus – Early beginnings for Alzheimer’s vaccines

  

This week Lingmed shares with you a research article on latest clinical trial progress of Alzheimer’s vaccines.


Alzheimer's disease (AD) is the most common form of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. According to WHO, there are about 47.5 million patients worldwide, with 7.7 million new cases each year. Considering worldwide aging population, Alzheimer's disease has become a public health issue. This article introduce you the latest clinical trials progress for Alzheimer’s vaccines 

Dismal past and The years ahead

The latest clinical trial progress of three Beta-amyloid-specific assets

The latest clinical trial progress of two Tau-to-tangle assets


想要下载完整报告? 

请登录 www.lingmed.net/reports

或点击下方“阅读原文”马上下载